ProCE Banner Activity

Updated Results From Phase I/II MajesTEC-1 Study: Teclistamab, a BCMA x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Teclistamab showed promising efficacy of 62% ORR with favorable tolerability in patients with triple-class–exposed R/R MM.

Released: December 17, 2021

Expiration: December 16, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation